Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma
Department of Pediatrics, Division of Pulmonary and Allergy; Horae Gene Therapy Center; Office of the Dean; Department of Microbiology and Physiological Systems
Cancer Biology | Genetics and Genomics | Neoplasms | Therapeutics
In a recent Nature Genetics letter, entitled “Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas,” Nault and colleaguesdocument that of 193 patients with hepatocellular carcinoma (HCC), 11 contained an integrated genome sequence of the wild-type adeno-associated virus 2 (AAV2), and suggest that AAV2 is associated with oncogenic insertional mutagenesis in human HCC.
Because AAV2 has long been known to be a nonpathogenic human parvovirus and, in fact, has been shown to possess antitumor activity, it is critical that the scientific and clinical implications of these studies be rigorously assessed to justify their conclusions. We have carefully analyzed the data presented by Nault and colleaguesand reached a conclusion that is at variance with that of the authors.
DOI of Published Version
Hum Gene Ther. 2015 Dec;26(12):779-81. doi: 10.1089/hum.2015.29014.kib. Link to article on publisher's site
Human gene therapy
Berns, Kenneth I.; Byrne, Barry J.; Flotte, Terence R.; Gao, Guang Ping; Hauswirth, William W.; Herzog, Roland W.; Muzyczka, Nicholas; VandenDriessche, Thierry; Xiao, Xiao; Zolotukhin, Sergei; and Srivastava, Arun, "Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma" (2015). Pediatric Publications and Presentations. 73.